flanders.bio is a dynamic, member driven organisation with currently more than 350 members from Belgium and abroad. We help our members to create value by organising Networking and Training Activities, supporting Internationalisation, providing Services and building Expertise. flanders.bio and its members want to be the proud advocates of a reputable global-impact ecosystem in life sciences.
News from flanders.bio and its members
flanders.bio joins forces with FIT to support the internationalisation of Flanders’ economy
It’s official: flanders.bio has reached a structural collaboration agreement with Flanders Investment & Trade (FIT), Flanders’ agency for international enterprise. The agreement was signed today by Henk Joos, Managing Director at flanders.bio and Claire Tillekaerts, CEO at FIT, during an official ceremony at the Hotel Errera in Brussels. Flanders’ Minister-President Geert Bourgeois also attended the ceremony, formally sealing the reinforced collaboration. This partnership is embedded within ‘Vlaanderen versnelt!’ (‘Flanders accelerates!’), Flanders’ internationalization strategy.
Newly described process in Parkinson’s protein as a potential new therapy route
An international group of researchers led by Professor Wim Versées (VIB-VUB) has unraveled the workings of an essential mechanism in ‘Parkinson’s protein’ LRRK2. Their study demonstrates a direct link between the protein’s ‘dimerization’ – two copies that are bound together –and mutations that lead to Parkinson’s disease. This process could eventually lead to a promising therapy route. This research has been published in the leading academic journal Nature Communications.
Imec en de UGent openen HomeLab
Gisteren openden imec en de UGent op het technologiepark in Zwijnaarde HomeLab, een digitale leef- en leeromgeving die de woning van de toekomst als uitgangspunt neemt – en waar bedenkers, designers, ontwikkelaars en testgebruikers slimme diensten en producten kunnen ontwikkelen en/of testen.
ONTOFORCE wins the EIT Venture Award 2017
ONTOFORCE has won the EIT Venture Award 2017 for its semantic search platform DISQOVER. This award – one of three awarded by the European Institute of Innovation & Technology – recognises Europe’s most promising ventures. The jury acknowledged ONTOFORCE’s passion and societal impact in democratizing Big Data in Life Sciences, and beyond.
Ablynx announces launch of proposed global offering
Ablynx NV [Euronext Brussels: ABLX; OTC: ABYLY], a late-stage clinical biopharmaceutical company utilising its proprietary Nanobody® platform to develop treatments for a broad range of therapeutic indications with an unmet medical need, announced today that it intends to offer and sell, subject to market and other conditions, approximately $175 million of its ordinary shares in a global offering, which is comprised of a public offering in the United States and Canada of ordinary shares in the form of American Depositary Shares ("ADS"), and an offer of ordinary shares in Europe and countries outside of the United States and Canada in a concurrent private placement. Investors other than qualified investors under applicable law will not be eligible to participate in this private placement.